Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST Nov 8, 2008
NEW YORK, Nov. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ) will hold a conference call on Tuesday, November 11, 2008 at 8:30 a.m. EST to discuss the third quarter 2008 financial results ... About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer ... KERYX CONTACT:... (PR Newswire)
An Israeli Biotech Company Plays the Field Jul 4, 2008
A doctor-turned-drug developer, Laster was previously involved in founding, and taking public, two Israeli biotechs, XTL Biopharmaceuticals () and Keryx Biopharmaceuticals (). BioLineRX's scientific advisory board is headed by a Nobel laureate in chemistry, Aaron Ciechanover. (BusinessWeek)
AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results May 8, 2008
The increase in revenues is primarily related to additional sales of Cetrotide(R) to Merck Sereno, mainly offset by decreased sales activities of Impavido(R) and Cetrotide(R) in Japan, as well as a reduction in license fees revenues related to services rendered through our collaborations with Spectrum Pharmaceuticals, Inc. and Keryx Biopharmaceuticals, Inc. Consolidated selling, general and administrative (SGenses were $4. 4 million for the three-month period ended March 31, 2008 compared to $4. (Canada Newswire)
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan Apr 5, 2008
Plan includes refocusing of operations and workforce reduction NEW YORK, April 4, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: ) today announced that it is implementing a strategic restructuring plan to reduce its cash burn rate and re-focus its development efforts ... Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "This has been a challenging process, but through these measures we believe that we have designed a strategy by which we will... (PR Newswire)
Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial Mar 28, 2008
NEW YORK, March 27 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ) announced today that following a Drug Safety and Monitoring Committee (DSMC) review of the SUN-MACRO Phase 4 trial of Sulonex(TM) (sulodexide oral gelcap), the Company has decided to terminate the study and cease further development of Sulonex ... About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel... (PR Newswire)
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised) Mar 21, 2008
Co., Ltd. (TSE: 1720) Taisho Pharmaceutical Co., Ltd. (TSE: 4535) Diagnostics Index (HHD) Drop CR Bard, Inc. (NYSE: ) IDEXX Laboratories (Nasdaq: ) Add Bruker Corporation (Nasdaq: ) Halozyme Therapeutic (Nasdaq: ) Emerging Cancer Index (HHJ) Drop Adventrx Pharmaceuticals, Inc. (Amex: ) Keryx Biopharmaceuticals, Inc. (Nasdaq: ) Add Dyanvax Technologies (Nasdaq: ) Synta Pharmaceuticals Corp. (Nasdaq: ) Enabling Technologies Index (HHV) Drop Hillenbrand Industries (NYSE: ) Add Eurand N.V. (Nasdaq:... (PR Newswire)
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint Mar 8, 2008
Company to host a conference call Monday, March 10, 2008 at 8:30am NEW YORK, March 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ) today announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy ... ABOUT KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of... (PR Newswire)
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results Feb 23, 2008
Keryx to Host Investor Conference Call on Monday, February 25, 2008 at 8:30am EST NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2007 ...... (PR Newswire)
Multiple Myeloma Research Consortium (MMRC) Honors Emory University, Dr. Sagar Lonial With 2007 Center of the Year Award Dec 8, 2007
two Phase II studies of Carfilzomib (PR-171), a proteasome inhibitor, in collaboration with by Proteolix, Inc.; * a Phase II study of LBH589, a deacetylase inhibitor, in collaboration with Novartis Pharmaceuticals; * a Phase I study of NPI-0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals; and * a Phase I study of perifosine, Revlimid(r), and dexamethasone in collaboration with Keryx Biopharmaceuticals. ADVERTISEMENT. (Primezone Releases)
Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance Sep 26, 2007
Conference Call to Be Held Tomorrow, Wednesday, September 26th at 8:30am NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ) announced today that it will conduct a conference call to discuss a strategic alliance surrounding one of its Phase II portfolio products for a territory outside the US. The call will take place tomorrow, Wednesday, September 26, 2007, at 8:30am EDT. Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals will host the call ...... (PR Newswire)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Sep 18, 2007
5 Keryx Biopharmaceuticals KERX 120857724. 8 MARSHALL EDWARDS INC MSHL 363211374. (PR Newswire)
Phase II Study Of Deacetylase Inhibitor For Multiple Myeloma Patients Aug 16, 2007
In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID), and dexamethasone in collaboration with Keryx Biopharmaceuticals. "Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this... (eMaxHealth.com)
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting Jun 4, 2007
Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors QUEBEC CITY, QC, June 4 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx Biopharmaceuticals (NASDAQ: KERX) presented a poster outlining Phase 1 and Phase 2 results for perifosine, an oral anti-cancer signal transduction inhibitor compound, for the treatment of patients... (Canada Newswire)
Keryx Biopharmaceuticals, Inc. Announces Appointment of Kevin J. Cameron to Board of Directors Apr 26, 2007
NEW YORK, April 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ) today announced the appointment of Kevin J. Cameron, to the Company's Board of Directors ... Weiss continued, "Kevin's extensive experience with important issues surrounding accounting, financial transparency, and corporate governance as well his pro-shareholder philosophy will further strengthen the Company's commitment to corporate compliance." ABOUT KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals,... (PR Newswire)
Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel & Chief Compliance Officer Apr 26, 2007
Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel Compliance Officer ... Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel Compliance Officer ... NEW YORK, April 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: ) today announced that Beth F. Levine, Esq. (PR Newswire)
Keryx Biopharmaceuticals Names Mark Stier, CPA Chief Accounting Officer Mar 28, 2007
NEW YORK, March 27 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: ) today announced that Mark Stier, CPA, has joined the Company as Vice President and Chief Accounting Officer, with responsibility for overseeing all accounting practices and policies for the organization ... ABOUT KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of... (PR Newswire)
